FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGE	S IN BENEFIC	CIAL OWNERS	HIP

l	OMB APPROVAL									
	OMB Number:	3235-0287								
	Estimated average burde	en								
l	hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Berg Aaron  (Last) (First) (Middle)  C/O AMARIN PHARMA, INC.  440 US HIGHWAY 22											g Symbol K [ AMRN	(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  Officer (give title Other (specify						
						3. Date of Earliest Transaction (Month/Day/Year) 12/16/2019									X Officer (give title Officer (specify below)  CHIEF COMMERCIAL OFFICER				
(Street) BRIDGEWATER NJ 08807				_	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person					
(City)	(3)		(Zip)	lon-Deri	vativ	o Soc	·urit	ios Ac	rauiro	d D	ienoead o	f or Re	noficial	ly Owne	٠				
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/N			tion	on 2A. Deemed Execution Date,		ed Date,	3. Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar		(A) or	5. Amo Securi Benefi Owned	unt of ties cially Following	Form:	: Direct · Indirect str. 4)	7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) or (D)	Price	Report Transa (Instr.	rted action(s) 3 and 4)			(Instr. 4)		
Ordinary Shares <sup>(1)(2)</sup> 12/16/20					2019	19		M		43,253	Α	\$12.6	17	7,059		D			
Ordinary Shares <sup>(1)(2)</sup> 12/16/20				2019	)19		S		43,253	D	\$25.4633	133	133,806(4)		D				
		•	Table I								posed of, , convertil			Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution D	ion Date,	Date, Transa Code (				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerci	isable	Expiration Date	Title	Amount or Number of Shares	ber					
Stock Option (Right to	\$12.6	12/16/2019			M			43,253	(5	5)	12/02/2022	Ordinary Shares <sup>(2)</sup>		\$0.00	0		D		

## **Explanation of Responses:**

- 1. The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
- 2. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents on Ordinary Share.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$25.31 to \$25.674, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 4. Please see the section titled "Remarks" below for additional information.
- 5. The shares subject to this option are fully vested as of the date hereof.

## Remarks:

As of the date of this Form 4, the Reporting Person owns or holds the right to acquire an aggregate of 823,888 Ordinary Shares of the Issuer in the form of Ordinary Shares, stock options and RSUs granted under the Amarin Corporation plc 2011 Stock Incentive Plan, including but not limited to certain performance-based Restricted Stock Units that are earned only if product revenues reach pre-defined annual milestone levels and, in certain cases, then vest only if the recipient remains with the company for an extended period of time

> /s/ Joseph Kennedy, by power of attorney

12/18/2019

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.